FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

The federal agency is requiring all GLP-1 s to include information about the potential risk on warning labels

The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness .

On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, also known as NAION, on warning labels. Continue reading...

Read the full story at theguardian.com

Recommended

General

Ukrainian Embassy calls "Glory to UPA" graffiti in Poland manifestation of Russian hybrid warfare

General

New prostate cancer guidelines urge men to start screening at specific age

Technology

Checking your Apple Watch's battery health is easier than you think